How uterine fibroids look on ultrasound during relugolix, estradiol and norethisterone treatment
Looks at ultrasound changes in fibroids of women taking relugolix, estradiol and norethisterone.
Key facts
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study
- Status
- Recruiting
- People taking part
- 111 people, planned
- Started
- 2 May 2025
- Expected to end
- 2 May 2027
- Type of study
- Observational
- Treatments tested
- Relugolix/estradiol/norethisterone acetate
- Record updated
- 17 August 2025
Who can take part
The trial is looking for women before menopause with benign uterine fibroids that cause abnormal uterine bleeding. They take relugolix/estradiol/norethisterone acetate by mouth, and the trial follows how the fibroids look on ultrasound.
- Age
- 18 years and older
- Sex
- Women only
- Disease stage
- Before menopause. A non-cancerous lesion in the uterine muscle, seen on ultrasound. It causes symptoms such as heavy or irregular bleeding. The lesion must be larger than 10 mm.
- Biomarker or test result
- Ultrasound images must be available in digital format.
- Main reasons for not taking part
- Women after menopause, or women with fibroids that cause no symptoms
- Ultrasound shows a lesion that may be cancer
- Past cancer or pre-cancer of the uterus or cervix
- Ovarian disease, or current treatment for another cancer
- No digital ultrasound images, or images too poor to describe the lesion
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Age ≥ 18 years
- Pre-menopausal status
- Ultrasound diagnosis of benign myometrial lesion
- Symptomatic patients presenting with abnormal uterine bleeding (menorrhagia/metrorrhagia)
- Availability of ultrasound images in digital format
Who cannot take part
- Myometrial formation suspected of malignancy on ultrasound (e.g., STUMP - Uterine Leiomyosarcoma)
- Personal history of malignant or premalignant uterine neoplasia (e.g., STUMPs, leiomyosarcoma, atypical endometrial hyperplasia, endometrial carcinoma, cervical carcinoma)
- Patients currently undergoing treatment for another malignancy
- Age < 18 years
- Patient refusal
- Postmenopausal women
- Myometrial lesion ≤ 10 mm
- Asymptomatic patients with uterine fibromatosis
- Patients with ovarian pathology
- Patients lacking available digital ultrasound images or whose image quality is insufficient to adequately characterize the target lesion's ultrasound features
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.
Read full original descriptionShow less
Ultrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.
The group in the trial
- Uterine fibroids symptomatic for abnormal uterine bleeding
Patients with ultrasound diagnosis of uterine fibroids, symptomatic for abnormal uterine bleeding, eligible for oral medical therapy with relugolix/estradiol/norethisterone
Treatment: Relugolix/estradiol/norethisterone acetate
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study
- Plain-language title
- How uterine fibroids look on ultrasound during relugolix, estradiol and norethisterone treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06953076, who can take part
- Record updated
- 17 August 2025